Abstract
In This Issue.
Dyslipidemia is a key independent risk factor for cardiovascular disease
(CVD); CVD is the largest therapeutic segment of the world pharmaceutical
market, and treatment of dyslipidemia represents a major sector of the CVD
market. This report provides an overview of the condition, its role in CVD,
and its prevalence. We discuss dyslipidemia treatments, with a focus on the
statins as the dominant treatment choice worldwide. We review key patent
expiries, including the imminent U.S. expiries of pravastatin (Bristol-Myers
Squibb's Pravachol) and simvastatin (Merck & Co.'s Zocor) and the expected
2011 patent expiry of the best-selling statin, atorvastatin (Pfizer's
Lipitor). In addition, we discuss emerging agents in this market, highlighting
the effect generic agents may have on their adoption, or the effect these new
agents may have on generics erosion of the market. Finally, we present our
expectations for the market throughout our 2004-2014 forecast period.
View Cart
